Comparing Two Chemotherapy Regimens for Advanced Breast Cancer
Author Information
Author(s): D.I. Jodrell, I.E. Smith, J.L. Mansil, M.C. Pearson, G. Walsh, S. Ashley, H.D. Sinnett, J.A. McKinnal
Primary Institution: Royal Marsden Hospital
Hypothesis
Is the new chemotherapy regimen MMM more effective than the standard CMF regimen for treating advanced breast cancer?
Conclusion
The study found that the new chemotherapy regimen MMM is as effective as the standard CMF regimen, with similar response rates and survival times.
Supporting Evidence
- 29 out of 57 patients treated with MMM achieved an objective response.
- 33 out of 55 patients treated with CMF achieved an objective response.
- The overall median survival was 16 months for MMM and 12 months for CMF.
- Diarrhoea occurred in 50% of patients treated with CMF compared to 21% for MMM.
- Thrombocytopenia was significantly increased in MMM (34% vs 14%).
- No clinical cardiotoxicity was seen in either group.
Takeaway
Doctors tested two treatments for breast cancer to see which one works better. They found that both treatments help patients live longer and feel better.
Methodology
Patients were randomly assigned to receive either the MMM or CMF chemotherapy regimen, and their responses were evaluated based on standard criteria.
Potential Biases
Potential bias due to the non-stratified randomization and the exclusion of patients with significant comorbidities.
Limitations
The study had a relatively small sample size and did not include patients who had previously received chemotherapy.
Participant Demographics
Median age was 55 years for CMF and 51 years for MMM; 37% were pre- or perimenopausal for CMF and 42% for MMM.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% confidence limits 38-64% for MMM and 47-73% for CMF
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website